Alan List - Apr 26, 2024 Form 4 Insider Report for PRECISION BIOSCIENCES INC (DTIL)

Role
Chief Medical Officer
Signature
/s/ Dario Scimeca, Attorney-in-Fact for Alan List
Stock symbol
DTIL
Transactions as of
Apr 26, 2024
Transactions value $
-$2,386
Form type
4
Date filed
4/30/2024, 06:34 PM
Previous filing
Jan 23, 2024
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DTIL Common Stock Options Exercise +868 +27.42% 4.03K Apr 26, 2024 Direct F1, F2, F3
transaction DTIL Common Stock Sale -$2.39K -238 -5.9% $10.03 3.8K Apr 30, 2024 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DTIL Restricted Stock Units Options Exercise $0 -868 -100% $0.00* 0 Apr 26, 2024 Common Stock 868 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on April 26, 2024.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F3 On February 13, 2024, the Issuer effected a 1-for-30 reverse stock split. The amounts of securities herein have been adjusted to reflect the reverse stock split.
F4 The sales were effected pursuant to a Rule 10b5-1 plan adopted on March 24, 2022. The transaction was a sell-to-cover, with shares only sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The Reporting Person did not sell or otherwise dispose of shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.85 to $10.14. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F6 On June 7, 2021 the Reporting Person was granted RSUs, which vest in three substantially equal annual installments beginning on April 26, 2022, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.